"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
| Descriptor ID |
D060828
|
| MeSH Number(s) |
E02.319.499 E02.860.500
|
| Concept/Terms |
Induction Chemotherapy- Induction Chemotherapy
- Chemotherapies, Induction
- Chemotherapy, Induction
- Induction Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".
This graph shows the total number of publications written about "Induction Chemotherapy" by people in this website by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.
-
An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
-
[Acute promyelocytic leukemia complicated with central nervous system involvement successfully treated with all-trans retinoic acid via nasogastric tube]. Rinsho Ketsueki. 2022; 63(1):26-30.
-
Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2021 04 06; 113(4):408-417.
-
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 06; 27(6):490.e1-490.e8.
-
Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021 01 15; 127(2):275-283.
-
Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
-
Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.